{"preliminary_commentary":{"by_channel":{"x_thread":23,"youtube":4,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04812366\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["apalutamide"],["apalutamide","abiraterone","prednisone"],["abiraterone","prednisone"]],"indication":"high-risk localized prostate cancer","name":"GUNS","nct_id":"NCT04812366","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=guns-nct04812366. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"GUNS","arms":[{"description":"LHRHa plus apalutamide.","label":"Group 1a","type":"ACTIVE_COMPARATOR"},{"description":"LHRHa plus apalutamide plus abiraterone acetate plus prednisone.","label":"Group 1b","type":"ACTIVE_COMPARATOR"},{"description":"LHRHa plus abiraterone acetate plus prednisone.","label":"Group 2a","type":"ACTIVE_COMPARATOR"},{"description":"LHRHa plus abiraterone acetate plus prednisone plus docetaxel.","label":"Group 2b","type":"ACTIVE_COMPARATOR"},{"description":"LHRHa plus abiraterone acetate plus prednisone plus niraparib","label":"Group 3","type":"ACTIVE_COMPARATOR"},{"description":"LHRHa plus apalutamide plus atezolizumab","label":"Group 4","type":"ACTIVE_COMPARATOR"},{"description":"LHRHa plus abiraterone acetate plus prednisone plus tazemetostat","label":"Group 5","type":"ACTIVE_COMPARATOR"},{"description":"LHRHa plus abiraterone acetate plus prednisone plus Capivasertib","label":"Group 6","type":"ACTIVE_COMPARATOR"}],"collaborators":["Janssen Inc.","University Health Network, Toronto"],"completion_date":{"date":"2027-06-01","type":"ESTIMATED"},"conditions":["Prostate Cancer"],"enrollment":{"count":315,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Apalutamide 60mg Tab","otherNames":[],"type":"DRUG"},{"name":"Abiraterone Acetate 250mg","otherNames":[],"type":"DRUG"},{"name":"Prednisone 5mg Tab","otherNames":[],"type":"DRUG"},{"name":"Docetaxel","otherNames":[],"type":"DRUG"},{"name":"Niraparib 100mg Oral Capsule","otherNames":[],"type":"DRUG"},{"name":"Atezolizumab","otherNames":[],"type":"DRUG"},{"name":"Tazemetostat Pill","otherNames":[],"type":"DRUG"},{"name":"Capivasertib","otherNames":[],"type":"DRUG"}],"last_update":"2026-08-14","lead_sponsor":"University of British Columbia","official_title":"Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-06-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Complete Pathologic Response (pCR)","timeFrame":"6 years"},{"measure":"Pathological Minimal Residual Disease (pMRD)","timeFrame":"6 years"}],"references":[],"start_date":{"date":"2021-09-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT04812366"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/guns-nct04812366"}